{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Giredestrant",
  "nciThesaurus": {
    "casRegistry": "1953133-47-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.",
    "fdaUniiCode": "28P3DU6DB3",
    "identifier": "C147030",
    "preferredName": "Giredestrant",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C2116"
    ],
    "synonyms": [
      "GDC 9545",
      "GDC-49545",
      "GIREDESTRANT",
      "Giredestrant",
      "RG6171",
      "SERD GDC-9545",
      "Selective Estrogen Receptor Degrader GDC-9545",
      "Selective Estrogen Receptor Downregulator GDC-9545"
    ]
  }
}